PAROXETINE CONTROLLED RELEASE COMPOSITIONS

Abstract: A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSR1) such as paroxetine.

Description: PAROXETINE CONTROLLED RELEASE COMPOSITIONS The present invention relates to a novel formulation containing paroxetine or a pharmaceutically acceptable salt thereof, and to its use in the treatment and/or prophylaxis of certain disorders. US Patent No 4,007,196 describes inter alia a compound which is commonly known as paroxetine. This compound is a Selective Serotonin Reuptake Inhibitor (SSRl) and is currently marketed world-wide for the treatment and/or prophylaxis of depression. The current formulation which is the only marketed formulation of paroxetine hydrochloride is a swallow tablet. It has now been surprisingly found that controlled release and delayed release formulations containing paroxetine give rise to an unexpected reduction in the side effects associated with swallow tablets. Accordingly, the present invention provides a controlled release or delayed release formulation containing paroxetine or a pharmaceutically acceptable salt thereof. A further aspect of the invention provides a controlled release or delayed release formulation containing an SSRl. Examples of SSRIs other than paroxetine include fluoxetine (US Patent No. 4,314,081), fluvoxamine (US Patent No. 4,085,225), and sertraline (US Patent No. 4,536,518). By controlled release is meant any formulation technique wherein release of the active substance from the dosage from is modified to occur at a slower rater than that from an immediate release product, such as a conventional swallow tablet or capsule. By delayed release is meant any formulation technique wherein release of the active substance from the dosage form is modified to occur at a later time than that from a conventional immediate release product. The subsequent release of active substance from a delayed release formulation may also be controlled as defmed above. Examples of controlled release formulations which are suitable for incorporating paroxetine and other SSRIs are described in: Sustained Release Medications, Chemical Technology Review No. 177. Ed. J.C. Johnson. Noyes Data Corporation 1980. Controlled Drug Delivery, Fundamentals and Applications, 2nd Edition. Eds. J.R. Robinson, V.H.L. Lee. Mercel Dekkes Inc. New York 1987. Examples of delayed release formulations which are suitable for incorporating paroxetine and other SSRIs are described in: Remington's Pharmaceutical Sciences 16th Edition, Mack Publishing Company 1980, Ed. A. Osol. Such controlled release formulations are preferably formulated in a manner such that release of active substance such as paroxetine is effected predominantly during the passage through the stomach and the small intestine, and delayed release formulations are preferably formulated such that release of active substance such as paroxetine is avoided in the stomach and is effected predominantly during passage through the small intestine Said formulations are preferably formulated such that the release of the active substance is predominantly I to 3 hours post ingestion. The small intestine is suitably the duodenum, the ileum or the jejunem. Patients who benefit most from the formulations of the present invention are those who are known to suffer from nausea upon oral administration using swallow tablets. Preferred formulations are ultimately enteric coated tablets or caplets, wax or polymer coated tablets or caplets or time-release matrices, or combinations thereof. Particularly preferred formulations are described in US Patent No. 5,102,666. Thus, a particular aspect of the invention provides a polymeric controlled release composition comprising a reaction complex formed by the interaction of (1) a calcium polycarbophil component which is a water-swellable, but water insoluble, fibrous cross-linked carboxy-functional polymer, said polymer containing (a) a plurality of repeating units of which at least about 80% contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5% cross-linking agent substantially free from polyalkenyl polyether, said percentages being based upon the weights of unpolymerised repeating unit and cross-linking agent, respectively, with (2) water, in the presence of an active agent selected from the group consisting of SSRIs such as paroxetine. The amount of calcium polycarbophil present is from about 0.1 to about 99% by weight, for example about 10%. The amount of active agent present is from about 0.0001 to about 65% by weight, for example between about 5 and 20%. The amount of water present is from about 5 to about 200% by weight, for example between about 5 and 10%. The interaction is carried out at a pH of between about 3 and about 10, for example about 6 to 7. The calcium polycarbophil is originally present in the form of a calcium salt containing from about 5 to about 25% calcium. Further particularly preferred formulations are described in US Patent No. 5,422,123. Thus, a further particular aspect of the invention provides a system for the controlled release of an active substance which is an SSRl such as paroxetine, comprising (a) a deposit-core comprising an effective amount of the active substance and having defined geometric form, and (b) a support-platform applied to said deposit-core, wherein said deposit-core contains at least the active substance, and at least one member selected from the group consisting of (1) a polymeric material which swells on contact with water or aqueous liquids and a gellable polymeric material wherein the ratio of the said swellable polymeric material to said gellable polymeric material is in the range 1:9 to 9:1, and (2) a single polymeric material having both swelling and gelling properties, and wherein the support-platform is an elastic support, applied to said deposit-core so that it partially covers the surface of the deposit-core and follows changes due to hydration of the deposit-core and is slowly soluble and/or slowly gellable in aqueous fluids. The support-platform may comprise polymers such as hydroxypropylmethylcellulose, plasticizers such as a glyceride, binders such as polyvinylpyrrolidone, hydrophilic agents such as lactose and silica, and/or hydrophobic agents such as magnesium stearate and glycerides. The polymer(s) typically make up 30 to 90% by weight of the support-platform, for example about 35 to 40%. Plasticizer may make up at least 2% by weight of the support- platform, for example about 15 to 20%. Binder(s), hydrophilic agent(s) and hydrophobic agent(s) typically total up to about 50% by weight of the support- platform, for example about 40 to 50%. Paroxetine used in the present invention is suitably in the form of the free base or a pharmaceutically acceptable salt thereof. Preferably, paroxetine is suitably in the form of the hydrochloride hemihydrate. Paroxetine hydrochloride hemihydrate may be prepared according to the procedures generally outlined in US Patent 4,721,723.. Paroxetine in the form of a controlled release or delayed release formulation can be used to treat and prevent the following disorders: Alcoholism - Anxiety Depression Obsessive Compulsive Disorder Panic Disorder Chronic Pain Obesity Senile Dementia Migraine Bulimia Anorexia Social Phobia Pre-Menstrual Syndrome (PMS) Adolescent Depression Trichotillomania Dysthymia Substance Abuse These disorders are herein after referred to as "the disorders". The present invention provides a method of treating and/or preventing the disorders by administering an effective and/or a prophylactic amount of a controlled release or delayed release formulation containing paroxetine or a pharmaceutically acceptable salt thereof, to a sufferer in need thereof. The present invention further provides the use of a controlled release or delayed release formulation containing paroxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament, for treating and/or preventing the disorders. The present invention also provides a pharmaceutical composition for use in the treatment and/or prevention of the disorders which comprises a controlled release or delayed release formulation containing paroxetine or a pharmaceutically acceptable salt thereof. The following examples illustrate the present invention. Intragranular % w/w Paroxetine Hydrochloride 11.45 Methocel E5 1.25 Lactose 12.3 Extragranular Methocel K100LV 30.0 Lactose 44.0 Magnesium Stearate 1.0 TOTAL 100.0 Example 2 (Ηvdrophilic Matrix) Intragranular % w/w Paroxetine Hydrochloride 11.45 Methocel E5 1.25 Lactose 12.3 Extragranular Methocel K100LV 27.5 Methocel K4M 7.5 Lactose 39.0 Magnesium Stearate 1.0 TOTAL 100.0 Example 3 (pH Sensitive Coat on 1 [mmediat Tablet Core %w/w Paroxetine Hydrochloride 11.45 Lactose 64.05 Microcrystalline Cellulose 20.0 Sodium Starch Glycollate 4.0 Magnesium Stearate 0.5 TOTAL 100.0 Tablet Coating (apply approximately 6-10% of tablet core weight) %w/w Hydroxypropylmethylcellulose Phthalate 90.0 Triacetin 10.0 Example 4 (pH Sensitive Coat on Immediate Release Core) Tablet Core as in Example 3 Tablet Coating (apply approximately 6-10% of tablet core weight) %w/w Cellulose Acetate Phthalate 90.0 Diethyl Phthalate 10.0 Example 5 (Controlled Release Coating on Immediate Release Core) Tablet Core as in Example 3 Tablet Coating (apply approximately 5-12% of tablet core weight) %w/w Eudragit RS 100 86.0 Dibutyl Phthalate 10.0 Talc 4.0 FD&C Yellow No. 6 0.01 Example 6 (pH Sensitive Coat on Controlled Release Core.) Tablet Core as in Example 3 Tablet Coating as in Example 3 Example 7 (Encapsulated Controlled Release Coated Beads) Pellet %w/w (approx) Non Pareil Seed 30 Paroxetine Hydrochloride 40 Gelatin 8 Lactose 20 Talc 2 Coating %w/w Glycerylmonostearate 36.6 Glyceryldistearate 53.4 White Wax 10.0 Example 8 (Controlled release bilayer tablet) Active Layer Component mg tablet Function Paroxetine Hydrochloride 22.89* Active Methocel K4M 15.00 Hydrogel polymer Lactose monohydrate 62.0 Hydrophilic agent Polyvinylpyrrolidone 3.0 Binder Magnesium stearate 1.0 Hydrophobic agent Syloid 244 1.0 Hydrophilic agent Support platform Component mg/tablet Function Compritol 888 15.04 Plasticizer Lactose monohydrate 29.32 Hydrophilic agent Polyvinylpyrrolidone 4.0 Binder Magnesium stearate 1.52 Hydrophobic agent Methocel E5 29.32 Hydrogel polymer Iron oxide 0.08 Colourant Total tablet weight 184.89mg 'Equivalent to 20mg paroxetine as free base. The powder blend for each layer was wet granulated in a high shear mixer/granulator and dried in a fluid bed drier. The bilayer tablets were compressed on a Manesty triple layer press. Example 9 (Enteric coated calcium polycarbophil formulation) Core Component mg/tablet Function Paroxetine Hydrochloride 22.89* Active Calcium polycarbophil 20.00 Matrix Lactose anhydrous 146.11 Hydrophilic agent/diluent Polyvinylpyrrolidone 10.0 Binder Magnesium stearate 1.0 Hydrophobic agent lubricant Water** 0.024 Granulating liquid Enteric coat Component mg tablleett Function Eudragit 22.19 Polymer Talc 1.53 Lubricant Triethyl citrate 1.00 Plasticizer Water** 24.6 Diluent Film coat Opadry pink 10.5 Film coat Water** 94.5 Diluent Polish coat Opadry clear 0.750 Water** 29.3 Diluent ♦ Equivalent to 20mg paroxetine as free base. **Removed during processing. The^ore constituents were wet granulated in a high shear mixer/granulator, and dried in a fluid bed drier. The magnesium stearate was then added and the mixture processed in a low shear mixer. The mix was then compressed on a B type rotary tablet press. Coating was carried out using an Accela cota. Example 10 (Controlled release bilayer tablet) Active Layer Component mg/tablet Function Paroxetine Hydrochloride 22.89* Active Methocel K4M 20.00 Hydrogel polymer Lactose monohydrate 60.0 Hydrophilic agent Polyvinylpyrrolidone 5.0 Binder Magnesium stearate 1.0 Hydrophobic agent Syloid 244 1.0 Hydrophilic agent Support platform Component mg/tablet Function Compritol 888 14.72 Plasticizer Lactose monohydrate 30.60 Hydrophilic agent Polyvinylpyrrolidone 2.80 Binder Magnesium stearate 0.80 Hydrophobic agent Methocel E5 30.60 Hydrogel polymer Syloid 244 0.40 Hydrophilic agent Iron oxide 0.08 Colourant Total tablet weight 189.89mg *Equivalent to 20mg paroxetine as free base. The process was as described in Example 8. Example 11 (Controlled release bilaver tablet. Active Layer Component mg/tablet Function Paroxetine Hydrochloride 22.89* Active Methocel K4M 15.00 Hydrogel polymer Lactose monohydrate 63.31 Hydrophilic agent Polyvinylpyrrolidone 2.0 Binder Magnesium stearate 1.0 Hydrophobic agent Syloid 244 0.40 Hydrophilic agent Support platform - as in Example 10. Total tablet weight 184.60mg ♦ Equivalent to 20mg paroxetine as free base. The process was as described in Example 8. Example 12 (Enteric coated controlled release bilayer tablet) Active Layer Component mg/tablet Function Paroxetine Hydrochloride 28.61* Active Methocel K4M 18.75 Hydrogel polymer Lactose monohydrate 79.14 Hydrophilic agent Polyvinylpynolidone 2.50 Binder Magnesium stearate 1.25 Hydrophobic agent Syloid 244 0.50 Hydrophilic agent 670 FC l/l-.l'.-O. Support platform Component mg/tablet Function Compritol 888 15.04 Plasticizer Lactose monohydrate 30.50 Hydrophilic agent Polyvinylpyrrolidone 4.00 Binder Magnesium stearate 0.80 Hydrophobic agent Methocel E5 29.32 Hydrogel polymer Syloid 244 0.32 Hydrophilic agent Iron oxide 0.02 Colourant Enteric coating Component mg/tablet Function Eudragit 13.27 Polymer Talc 3.31 Lubricant Triethyl citrate 1.33 Plasticizer Water** 36.25 Diluent Total tablet weight 228.66mg ♦ Equivalent to 25mg paroxetine as free base. **Removed during processing. The process was as described in Example 9. Example 13 GI tolerance study The design of the study is outlined below Subjects: Normal healthy volunteers Design: Parallel group, placebo controlled, double blind Treatment: (a) Placebo, (b) Immediate release paroxetine, (c)Example 8 formulation, (d) Example 8 formulation with enteric coating. Dosage: 30 mg once daily for 3 days Number of subjects: 452 evaluable (488 randomised, 485 evaluable) The study was conducted to compare the incidence, severity and duration of nausea and vomiting, and diarrhoea (theoretically if the controlled release formulations slow down absorption of paroxetine then, as paroxetine is known to be prokinetic to the GI tract there may be an increased incidence). Adverse experiences (AE) information was assessed each morning at the time of dosing and again 24 hours following the last dose. Investigators and subjects were given diary cards detailing how to classify severity of AEs in order to standardise as much as possible across all 6 centres. Of the 485 evaluable subjects, 18 (3.7%) withdrew, 17 because of adverse events. Subjects with nausea vomiting on the day of withdrawal were more common on (b) than either of (c) and (d). The incidence of nausea/vomiting and diarrhoea is shown in the table below: (b) (c) (d) Placebo Incidence of nausea 59% 49% 39% 13% Incidence of 15% 21% 20% 7% diarrhoea The incidence of nausea was increased for both (b) and placebo compared to the expected rates of approximately 25% and 5% respectively for volunteers at these dosages for 3 days duration. The overall incidence of nausea was less on (c) and (d) than on (b). The severity of nausea was also decreased as shown in the next table. Nausea severity (b) (c) (d) Placebo None 50 (41%) 63 (52%) 74 (61%) 104 (87%) Mild 45 (37%) 40 (33%) 30 (25%) 16 (13%) Moderate 21 (17%) 17 (14%) 15 (12%) 0 (0%) Severe 6 (5%) 1 d%) 3 (2%) 0 (0%) Severity of dianhoea is reported in the table below: Severity of diarrhoea (b) (c) (d) Placebo None 104 (85%) 95 (79%) 97 (80%) 112 (93%) Mild 16 (13%) 16 (13%) 16 (13%) 8 (7%) Moderate 1 (1%) 8 (7%) 9 (7%) 0 (0%) Severe 1 (1%) 2 (2%) 0 (0%) 0 (0%) In conclusion, there appears to be a trend for (c) to reduce the incidence of nausea and the dropout rate due to adverse events in comparison to (b), but analysis of the results was complicated by a statistically significant treatment-by-centre difference, (d) shows a halving in the dropout rate and a fall in incidence of nausea of 20% (a proportional fall of 33%). In addition there is a reduction in severity of nausea of those individuals who report nausea on (c) and (d). There is an increase in incidence of diarrhoea on both of (c) and (d) in relation to (b), but this is confined to an increase in the number of individuals reporting moderate dianhoea and there is no increase in those with severe dianhoea.

Claims: Claims 1. A controlled release or delayed release formulation containing a selective serotonin reuptake inhibitor (SSRl). 2. A formulation according to claim 1 wherein the SSRl is paroxetine or a pharmaceutically acceptable salt thereof. 3. A formulation according to claim 1 or 2, which comprises enteric coated tablets or caplets, wax or polymer coated tablets or caplets or time-release matrices, or combinations thereof. 4. A formulation according to any preceding claim, which is a polymeric controlled release composition comprising a reaction complex formed by the interaction of (1) a calcium polycarbophil component which is a water-swellable, but water insoluble, fibrous cross-linked carboxy-functional polymer, said polymer containing (a) a plurality of repeating units of which at least about 80% contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5% cross-linking agent substantially free from polyalkenyl polyether, said percentages being based upon the weights of unpolymerised repeating unit and cross-linking agent, respectively, with (2) water, in the presence of an active agent selected from the group consisting of SSRIs. 5. A formulation according to any one of claims 1 to 3, which is a system for the controlled release of an active substance which is an SSRl, comprising (a) a deposit-core comprising an effective amount of the active substance and having defined geometric form, and (b) a support-platform applied to said deposit-core, wherein said deposit-core contains at least the active substance, and at least one member selected from the group consisting of (1) a polymeric material which swells on contact with water or aqueous liquids and a gellable polymeric material wherein the ratio of the said swellable polymeric material to said gellable polymeric material is in the range 1:9 to 9:1, and (2) a single polymeric material having both swelling and gelling properties, and wherein the support-platform is an elastic support, applied to said deposit-core so that it partially covers the surface of the deposit-core and follows changes due to hydration of the deposit- core and is slowly soluble and/or slowly gellable in aqueous fluids. 6. A method of treating and/or preventing the disorders by administering an effective and/or a prophylactic amount of a controlled release or delayed release formulation according to any preceding claim, to a sufferer in need thereof. 7. Use of a controlled release or delayed release formulation according to any one of claims 1 to 5 in the manufacture of a medicament, for treating and or preventing the disorders. 8. A process for the preparation of a formulation according to any one of claims 1 to 5, which comprises combining the constituents thereof in the required proportions.

Inventors: EDLER DAVID PHILIP, LEONARD GRAHAM STANLEY, EDLER, DAVID, PHILIP, LEONARD, GRAHAM, STANLEY
Applicants: EDLER DAVID PHILIP, LEONARD GRAHAM STANLEY, SMITHKLINE BEECHAM PLC, EDLER, DAVID, PHILIP, LEONARD, GRAHAM, STANLEY, SMITHKLINE BEECHAM P.L.C.
Application year: 1996
Main classification: A61K31
IPC codes: A61K9, A61K31, A61K45, A61K47